Concepedia

Publication | Open Access

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

DOIFull Paper Access

975

Citations

13

References

2019

Year

Dung T. Le, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert H. O’Neil, Petr Kavan, Takayuki Yoshino,
Journal of Clinical Oncology

Abstract

Pembrolizumab is effective with a manageable safety profile in patients with MSI-H/dMMR CRC.

References

YearCitations

Page 1